Skip to main content
All lobbying filings

FEROX STRATEGIES

FEROX STRATEGIES filed a Q1 report for RARE DISEASE COMPANY COALITION on April 17, 2026, reporting $50,000 in lobbying income.

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

All filings by FEROX STRATEGIES · Everything RARE DISEASE COMPANY COALITION has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Trade (domestic/foreign)

General issues related to tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem